5-(3-氯苯基)-5-氧代戊酸 | 75381-46-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-(3-氯苯基)-5-氧代戊酸
• 英文名称: 5-(3-chlorophenyl)-5-oxopentanoic acid
• 英文别名: 5-(3-Chlorophenyl)-5-oxovaleric acid
• CAS: 75381-46-3
• 化学式: C₁₁H₁₁ClO₃
• 分子量: 226.66
• InChiKey: HFTNETNQJWKQFK-UHFFFAOYSA-N

物化性质

• 沸点：
  423.1±30.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918300090

反应信息

• 作为反应物：
  描述：

  5-(3-氯苯基)-5-氧代戊酸 在 sodium tetrahydroborate 、 N-羟基邻苯二甲酰亚胺 、 偶氮二甲酸二异丙酯 、 (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 2.67h， 生成 5-(aminooxy)-5-(3-chlorophenyl)-N-phenylpentanamide
  参考文献：
  名称：

  Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase

  摘要：

  Tryptophan (Trp) catabolizing enzymes play an important and complex role in the development of cancer. Significant evidence implicates them in a range of inflammatory and immunosuppressive activities. Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) have been reported and analyzed in the clinic, fewer inhibitors have been described for tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have been implicated more recently in cancer, inflammation and immune control. Consequently the development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a therapeutically important area of research. This is the first report to describe the development of dual and pan inhibitors of IDO1, TDO and IDO2. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.11.010
• 作为产物：
  描述：

  (3-氯苯甲酰)乙酸乙酯 在 氢溴酸 、 sodium ethanolate 作用下， 反应 7.5h， 生成 5-(3-氯苯基)-5-氧代戊酸
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of a new series of substituted benzoyl-γ-butyrolactone derivatives

  摘要：

  A series of substituted benzoyl-gamma-butyrolactones (1-3) has been synthesized and tested for their ability to affect central dopaminergic and GABAergic function in comparison to gamma-butyrolactone (GEL). Similarly to GEL, alpha-, beta- and gamma-substituted GBLs 1-3 with one or more chlorine on the phenyl ring were found to induce central depressant effects in rats, though at different degrees. However, the test compounds modified dopamine (DA) metabolism in rat striatum differently from GEL. In fact, whereas GEL increased both DA and dihydroxyphenylacetic acid (DOPAC) content, GEL derivatives 1-3 increased DA levels, but reduced the DOPAC concentration. Moreover, some of them, unlike GEL, effectively antagonized pentylenetetrazole (PTZ)-induced seizures in mice. In particular, alpha-3,5-dichlorobenzoyl-GBL (1g) was effective at a dose as low as 36 mg/kg in decreasing the number of animals having convulsions. However, in vitro addition and in vivo administration of the test compounds failed to modify [S-35]-t-butylbicyclo-phosphorothionate ([S-35]-TBPS) binding, which is a very sensitive tool for revealing changes in the GABAergic function.

  DOI：

  10.1016/0223-5234(96)88290-0

文献信息

• Iridium-Catalyzed Asymmetric Hydrogenation of γ- and δ-Ketoacids for Enantioselective Synthesis of γ- and δ-Lactones
  作者：Yun-Yu Hua、Huai-Yu Bin、Tao Wei、Hou-An Cheng、Zu-Peng Lin、Xing-Feng Fu、Yuan-Qiang Li、Jian-Hua Xie、Pu-Cha Yan、Qi-Lin Zhou

  DOI：10.1021/acs.orglett.9b04253

  日期：2020.2.7

  A highly efficient asymmetric hydrogenation of γ- and δ-ketoacids was developed by using a chiral spiro iridium catalyst (S)-1a, affording the optically active γ- and δ-hydroxy acids/lactones in high yields with excellent enantioselectivities (up to >99% ee) and turnover numbers (TON up to 100000). This protocol provides an efficient and practical method for enantioselective synthesis of Ezetimibe

  通过使用手性螺铱催化剂（S）-1a开发了高效的不对称氢化γ-和δ-酮酸，以高收率提供了光学活性的γ-和δ-羟基酸/内酯，对映选择性极好（高达> 99％ee）和营业额数字（TON最高为100000）。该协议为依泽替米贝的对映选择性合成提供了一种有效而实用的方法。
• Achiral Counterion Control of Enantioselectivity in a Brønsted Acid-Catalyzed Iodolactonization
  作者：Mark C. Dobish、Jeffrey N. Johnston

  DOI：10.1021/ja301858r

  日期：2012.4.11

  Highly enantioselective halolactonizations have been developed that employ a chiral proton catalyst-N-iodosuccinimide (NIS) reagent system in which the Brønsted acid is used at catalyst loadings as low as 1 mol %. An approach that modulates the achiral counterion (equimolar to the neutral chiral ligand-proton complex present at low catalyst loadings) to optimize the enantioselection is documented for

  已经开发出高度对映选择性卤内酯化反应，它采用手性质子催化剂-N-碘代琥珀酰亚胺 (NIS) 试剂系统，其中布朗斯台德酸以低至 1 mol% 的催化剂负载量使用。在该转化中首次记录了一种调节非手性抗衡离子（与低催化剂负载下存在的中性手性配体-质子复合物等摩尔）以优化对映体选择的方法。通过这种方式，使用市售 NIS 将不饱和羧酸以高产率（高达 98% ee）转化为 γ-内酯。
• Second-Layer Chiral Environment-Induced Steric Hindrance Enables Catalyst Conformation Lockdown in Enantioselective Hypervalent Iodine Organocatalysis
  作者：Xiaotao Zhang、Miaomiao Liu、Hao Ge、Zhipeng Zhang

  DOI：10.1021/acscatal.3c02018

  日期：2023.6.16

  A class of confined chiral hypervalent iodines have been designed and developed by incorporating two sterically demanding BINOL-derived units, which form the second-layer chiral environment, into the iodine-containing molecules to lock down the conformation of the catalyst and indirectly create a compact chiral environment around the active site. Good-to-excellent enantioselectivities have been achieved

  通过将两个空间要求高的 BINOL 衍生单元（形成第二层手性环境）结合到含碘分子中以锁定催化剂的构象并间接产生致密结构，设计和开发了一类受限手性高价碘活性位点周围的手性环境。这些催化剂在酮的 α-氧磺酰化（高达 97.5:2.5 er）和 5-oxo-5-arylpentanoic 酸氧化环化为 γ-丁内酯（高达 98:2）方面实现了良好至卓越的对映选择性呃），从而证明了这种策略在催化剂设计中的实用性。
• Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase
  作者：Maria Winters、James B. DuHadaway、Khoa N. Pham、Ariel Lewis-Ballester、Shorouk Badir、Jenny Wai、Eesha Sheikh、Syun-Ru Yeh、George C. Prendergast、Alexander J. Muller、William P. Malachowski

  DOI：10.1016/j.ejmech.2018.11.010

  日期：2019.1

  Tryptophan (Trp) catabolizing enzymes play an important and complex role in the development of cancer. Significant evidence implicates them in a range of inflammatory and immunosuppressive activities. Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) have been reported and analyzed in the clinic, fewer inhibitors have been described for tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have been implicated more recently in cancer, inflammation and immune control. Consequently the development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a therapeutically important area of research. This is the first report to describe the development of dual and pan inhibitors of IDO1, TDO and IDO2. (C) 2018 Elsevier Masson SAS. All rights reserved.
• Synthesis and pharmacological evaluation of a new series of substituted benzoyl-γ-butyrolactone derivatives
  作者：G Cignarella、D Barlocco、D Pocar、F Clerici、MM Curzu、GL Gessa、F Fadda、M Serra、G Biggio

  DOI：10.1016/0223-5234(96)88290-0

  日期：1995.1

  A series of substituted benzoyl-gamma-butyrolactones (1-3) has been synthesized and tested for their ability to affect central dopaminergic and GABAergic function in comparison to gamma-butyrolactone (GEL). Similarly to GEL, alpha-, beta- and gamma-substituted GBLs 1-3 with one or more chlorine on the phenyl ring were found to induce central depressant effects in rats, though at different degrees. However, the test compounds modified dopamine (DA) metabolism in rat striatum differently from GEL. In fact, whereas GEL increased both DA and dihydroxyphenylacetic acid (DOPAC) content, GEL derivatives 1-3 increased DA levels, but reduced the DOPAC concentration. Moreover, some of them, unlike GEL, effectively antagonized pentylenetetrazole (PTZ)-induced seizures in mice. In particular, alpha-3,5-dichlorobenzoyl-GBL (1g) was effective at a dose as low as 36 mg/kg in decreasing the number of animals having convulsions. However, in vitro addition and in vivo administration of the test compounds failed to modify [S-35]-t-butylbicyclo-phosphorothionate ([S-35]-TBPS) binding, which is a very sensitive tool for revealing changes in the GABAergic function.